Clinical Trials Logo

Clinical Trial Summary

This study will evaluate the safety and clinical activity of MRTX849 (adagrasib) in combination with palbociclib in patients with advanced solid tumor malignancies with KRAS G12C mutation.


Clinical Trial Description

This study will evaluate the pharmacokinetics and preliminary clinical activity of MRTX849 (adagrasib) in combination with palbociclib in patients with advanced solid tumor malignancies with KRAS G12C mutation. MRTX849 is an orally available small molecule inhibitor of KRAS G12C and palbociclib is a small molecule inhibitor of CDK 4 and 6. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05178888
Study type Interventional
Source Mirati Therapeutics Inc.
Contact Mirati Therapeutics Study Locator Services
Phone 1-844-893-5530
Email [email protected]
Status Recruiting
Phase Phase 1
Start date January 7, 2022
Completion date March 30, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With a PD-1 Inhibitor Phase 1/Phase 2
Active, not recruiting NCT02836600 - A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors Phase 1
Recruiting NCT04890613 - Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation Phase 1
Recruiting NCT04390737 - Evaluate the Safety and Clinical Activity of HH2853 Phase 1
Active, not recruiting NCT04108676 - Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects Phase 1
Active, not recruiting NCT05076396 - PM14 Administered Intravenously to Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04825392 - A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04592653 - A Study of ALKS 4230 (Nemvaleukin Alfa) on the Tumor Microenvironment Phase 2
Active, not recruiting NCT03704246 - Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors Phase 2
Recruiting NCT05002270 - JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation Phase 1/Phase 2
Recruiting NCT04478461 - Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Recruiting NCT04999384 - First in Human, Dose Escalation Study of AN4005 Phase 1
Recruiting NCT04135261 - A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors Phase 1
Recruiting NCT05071183 - A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors Phase 1/Phase 2
Completed NCT01387321 - A Study of BYL719 in Adult Patients With Advanced Solid Malignancies Phase 1
Recruiting NCT05021367 - A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor Phase 1
Not yet recruiting NCT05051241 - A Study of GFH018 in Patients With Advanced Solid Tumors Phase 1
Completed NCT01453387 - MSC2015103B in Solid Tumors Phase 1
Recruiting NCT05148325 - Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors Phase 1